Jessica Margareta Lindvall

Jessica Margareta Lindvall

Auto-generated profile, based on publicly available information

Jessica Margareta Lindvall

Stockholm University

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2005 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
JLJessica M. Lindvall
Jessica M. Lindvall
KBK. Emelie M. Blomberg
K. Emelie M. Blomberg
JVJouni Väliaho
Jouni Väliaho
LVLeonardo Vargas
Leonardo Vargas
JHJuhana E. Heinonen
Juhana E. Heinonen
CSC. I. Edvard Smith
C. I. Edvard Smith

1 March 2016 in Molecular Metabolism
Verified
Journal Article
Open access
HKHenriette Kirchner
Henriette Kirchner
ISIndranil Sinha
Indranil Sinha
HGHui Gao
Hui Gao
MRMaxwell A. Ruby
Maxwell A. Ruby
MSMilena Schönke
Milena Schönke
JZJuleen R. Zierath
Juleen R. Zierath
Epigenetic modifications contribute to the etiology of type 2 diabetes. We performed genome-wide methylome and transcriptome analysis in liver from severely obese men with or without type 2 diabetes and non-obese men to discover aberrant pathways underlying the development of insulin resistance. Results were validated by pyrosequencing. We identified hypomethylation of genes involved in hepatic glycolysis and insulin resistance, concomitant with increased mRNA expression and protein levels. Pyrosequencing revealed the CpG-site within ATF-motifs was hypomethylated in four of these genes in liver of severely obese non-diabetic and type 2 diabetic patients, suggesting epigenetic regulation of transcription by altered ATF-DNA binding. Severely obese non-diabetic and type 2 diabetic patients have distinct alterations in the hepatic methylome and transcriptome, with hypomethylation of several genes controlling glucose metabolism within the ATF-motif regulatory site. Obesity appears to shift the epigenetic program of the liver towards increased glycolysis and lipogenesis, which may exacerbate the development of insulin resistance.

25 March 2014 in Genome Biology
Verified
Journal Article
Open access
PDF file
CBCatherine A. Brownstein
Catherine A. Brownstein
ABAlan H. Beggs
Alan H. Beggs
NHNils Homer
Nils Homer
BMBarry Merriman
Barry Merriman
TYTimothy W Yu
Timothy W Yu
DMDavid M Margulies
David M Margulies
Background: There is tremendous potential for genome sequencing to improve clinical diagnosis and care once it becomes routinely accessible, but this will require formalizing research methods into clinical best practices in the areas of sequence data generation, analysis, interpretation and reporting. The CLARITY Challenge was designed to spur convergence in methods for diagnosing genetic disease starting from clinical case history and genome sequencing data. DNA samples were obtained from three families with heritable genetic disorders and genomic sequence data were donated by sequencing platform vendors. The challenge was to analyze and interpret these data with the goals of identifying disease-causing variants and reporting the findings in a clinically useful format. Participating contestant groups were solicited broadly, and an independent panel of judges evaluated their performance. Results: A total of 30 international groups were engaged. The entries reveal a general convergence of practices on most elements of the analysis and interpretation process. However, even given this commonality of approach, only two groups identified the consensus candidate variants in all disease cases, demonstrating a need for consistent fine-tuning of the generally accepted methods. There was greater diversity of the final clinical report content and in the patient consenting process, demonstrating that these areas require additional exploration and standardization. Conclusions: The CLARITY Challenge provides a comprehensive assessment of current practices for using genome sequencing to diagnose and report genetic diseases. There is remarkable convergence in bioinformatic techniques, but medical interpretation and reporting are areas that require further development by many groups.

15 March 2014 in Journal of Applied Physiology
Verified
Journal Article
Open access
PDF file
GNG. A. Nader
G. A. Nader
FWF. von Walden
F. von Walden
CLC. Liu
C. Liu
JLJ. Lindvall
J. Lindvall
LGL. Gutmann
L. Gutmann
PGPaul M. Gordon
Paul M. Gordon
We sought to determine whether acute resistance exercise (RE)-induced gene expression is modified by RE training. We studied the expression patterns of a select group of genes following an acute bout of RE in naïve and hypertrophying muscle. Thirteen untrained subjects underwent supervised RE training for 12 wk of the nondominant arm and performed an acute bout of RE 1 wk after the last bout of the training program ( training+acute). The dominant arm was either unexercised ( control) or subjected to the same acute exercise bout as the trained arm ( acute RE). Following training, men (14.8 ± 2.8%; P < 0.05) and women (12.6 ± 2.4%; P < 0.05) underwent muscle hypertrophy with increases in dynamic strength in the trained arm (48.2 ± 5.4% and 72.1 ± 9.1%, respectively; P < 0.01). RE training resulted in attenuated anabolic signaling as reflected by a reduction in rpS6 phosphorylation following acute RE. Changes in mRNA levels of genes involved in hypertrophic growth, protein degradation, angiogenesis, and metabolism commonly expressed in both men and women was determined 4 h following acute RE. We show that RE training can modify acute RE-induced gene expression in a divergent and gene-specific manner even in genes belonging to the same ontology. Changes in gene expression following acute RE are multidimensional, and may not necessarily reflect the actual adaptive response taking place during the training process. Thus RE training can selectively modify the acute response to RE, thereby challenging the use of gene expression as a marker of exercise-induced adaptations.

1 September 2003 in Leukemia
Verified
Journal Article
Open access
PDF file
TIT C Islam
T C Islam
AAA C Asplund
A C Asplund
JLJ M Lindvall
J M Lindvall
LNL Nygren
L Nygren
JLJ Liden
J Liden
BSB Sander
B Sander
Mantle cell lymphoma (MCL) is a moderately aggressive B-cell lymphoma that responds poorly to currently used therapeutic protocols. In order to identify tumour characteristics that improve the understanding of biology of MCL, analysis of oligonucleotide microarrays were used to define specific gene expression profiles. Biopsy samples of MCL cases were compared to reactive lymphoid tissue. Among genes differentially expressed in MCL were genes that are involved in the regulation of proliferation, cell signalling, adhesion and homing. Furthermore, some genes with previously unknown function, such as C11orf32, C2orf10, TBC1D9 and ABCA6 were found to be differentially expressed in MCL compared to reactive lymphoid tissue. Of special interest was the high expression of the cannabinoid receptor 1 (CB1) gene in all MCL cases analysed. These results were further confirmed at the cellular and protein level by immunocytochemical staining and immunoblotting of MCL cells. Furthermore, there was a reduced expression of a regulator of G protein signalling, RGS13 in all MCLs, with a complete absence in the majority of cases while present in control lymphoid tissue. These results were further confirmed by PCR. Sequencing of the RGS13 gene revealed changes suggesting polymorphisms, indicating that downregulation of the expression of RGS13 is not related to mutations, but may serve as a new specific marker for MCL. Moreover, comparison between individual cases of MCL, revealed that the CCND1 gene appears to be differently expressed in MCL cases with high vs low proliferative activity.

1 July 2016 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
VMVicente Martínez-Redondo
Vicente Martínez-Redondo
PJPaulo R. Jannig
Paulo R. Jannig
JCJorge C. Correia
Jorge C. Correia
DFDuarte M.S. Ferreira
Duarte M.S. Ferreira
ICIgor Cervenka
Igor Cervenka
JRJorge L. Ruas
Jorge L. Ruas
Endurance and resistance exercise training induce specific and profound changes in the skeletal muscle transcriptome. PGC-1a; coactivators are not only among the genes differentially induced by distinct training methods, but also participate in the ensuing signaling cascades that allow skeletal muscle to adapt to each type of exercise. While endurance training preferentially induces PGC-1a1 expression, resistance exercise activates the expression of PGC-1a2, a3, and a4. These three alternative PGC-1a isoforms lack the arginine-serine (RS) and RNA Recognition Motifs (RRM) characteristic of PGC-1a1. Discrete functions for PGC-1a1 and a4 have been described, but the biological role of PGC-1a2 and a3 remains elusive. Here we show that different PGC-1a variants can affect target gene splicing through diverse mechanisms, including alternative promoter usage. By analyzing the exon structure of the target transcripts for each PGC-1a isoform, we were able to identify a large number of previously unknown PGC-1a2 and a3 target genes and pathways in skeletal muscle. In particular, PGC-1a2 seems to mediate a decrease in the levels of cholesterol synthesis genes. Our results suggest that the conservation of the N-terminal activation and repression domains (and not the RS/RRM) is what determines the gene programs and splicing options modulated by each PGC-1a isoform. By using skeletal muscle-specific transgenics for PGC-1a1 and a4, we could validate in vivo splicing events observed in in vitro studies. These results show that alternative PGC-1a variants can affect target gene expression both quantitatively and qualitatively, and identify novel biological pathways under the control of this system of coactivators.